Latest filing published 30 Jan 2018 for Intellia Therapeutics, Inc., €11.9M.
Filing timeline
BuySaleInsider track record
No signal scores available.
Caribou Biosciences, Inc.: trading record in brief
Caribou Biosciences, Inc. discloses dealings in Intellia Therapeutics, Inc. to SEC (Form 4). We count 2 filings; the first trade dates from 13 September 2017 and the latest from 29 January 2018.
Every open-market trade on record is a sale: 2 sales worth €11.9M. No amount is published for 1 filing, which the totals therefore leave out. In 2018 alone, the filings show no purchases and 1 sale.
The newest entry dates from 30 January 2018: an open-market sale of €11.9M, in Intellia Therapeutics, Inc. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Caribou Biosciences, Inc.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 550,645 shares@ US$26.78100.0% of flowCommon StockSEC:0001415889-18-000152:0
- 1,048,846 sharesCommon StockSEC:0001415889-17-001484:0
2 of 2 declarations
